Pacific Biosciences of California Stock Price, News & Analysis (NASDAQ:PACB)

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PACB shares.
View PACB analyst ratings or view top-rated stocks.

11 Wall Street analysts have issued 1 year price targets for Pacific Biosciences of California's shares. Their PACB share price targets range from $8.00 to $17.00. On average, they anticipate the company's stock price to reach $11.80 in the next year. This suggests a possible upside of 34.2% from the stock's current price.
View analysts price targets for PACB or view top-rated stocks among Wall Street analysts.

Pacific Biosciences of California's stock was trading at $8.18 at the beginning of the year. Since then, PACB shares have increased by 7.5% and is now trading at $8.79.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our PACB earnings forecast.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) announced its quarterly earnings data on Monday, October, 30th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.02. The biotechnology company had revenue of $55.70 million for the quarter, compared to the consensus estimate of $48.76 million. Pacific Biosciences of California had a negative net margin of 182.34% and a negative trailing twelve-month return on equity of 43.39%. The business's quarterly revenue was up 72.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.32) earnings per share.

ETFs with the largest weight of Pacific Biosciences of California (NASDAQ:PACB) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Global X Telemedicine & Digital Health ETF (EDOC), Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), AXS Green Alpha ETF (NXTE), ARK Innovation ETF (ARKK), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and BNY Mellon Innovators ETF (BKIV).

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

Pacific Biosciences of California's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (11.90%), Sumitomo Mitsui Trust Holdings Inc. (5.37%), FMR LLC (1.73%), Bank of New York Mellon Corp (1.76%), Lord Abbett & CO. LLC (1.37%) and Northern Trust Corp (1.05%). Insiders that own company stock include Christian O Henry, Eric Schaefer, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Michele Farmer, Oene Mark Van, Peter Fromen, Susan G Kim and William W Ericson.
View institutional ownership trends.

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.